Summary
Generally, the efficacy of an anticonvulsant drug is a function of the intensity of the seizure process and the drug concentration in plasma and tissues. Because of the variability of the seizure process among individuals, a universally effective drug plasma level is not to be expected. Rather a ‘desirable’ plasma level range for each drug can be defined, the lower limits being those levels above which the majority of patients are well controlled, the upper limits being determined by the onset of drug intoxication.
With the onset of administration of anticonvulsants in average doses, the maximum plasma levels and effect are reached only after several days or with some drugs, after several weeks of therapy. The lag time can be reduced with loading doses in the case of phenytoin or phenobarbitone (2 to 3 times the usual dose). For maintenance therapy phenytoin and phenobarbitone may be given in a single daily dose without marked fluctuations in the plasma levels.
Some variations in the plasma levels relative to particular doses do occur, but in the majority of patients predictable ranges of plasma levels relative to doses can be defined. Marked deviations from these expected ranges are however, not infrequent. Low levels are most frequently caused by patients’ failure to take the drug regularly. Rare causes for low plasma levels are malabsorption of the drug, or unusually rapid drug metabolism or elimination. High levels may be caused by ingestion of greater than the prescribed dose, by impaired drug metabolism or elimination (genetic or constitutional), or because of interactions with other drugs. Elevation of phenytoin plasma level to the toxic range has been caused by a number of drugs, most predictably with disulfiram, sulthiame and isoniazid. When the interfering drug cannot be discontinued, the phenytoin dosage must be reduced and a new dose titrated using the plasma level as the indicator.
In the treatment of petit mal, the order of preference of drugs is based on efficacy and safety, with ethosuximide the drug of choice, followed in order by trimethadione, paramethadione, methsuximide and phensuximide. In grand mal and focal epilepsies, phenytoin and phenobarbitone are the best understood and successful drugs. Primidone is also very effective. Carbamazepine can be used as an alternative. A number of other agents are available for use in combination with the prime drugs in highly refractory cases, or alone when the major drugs are contra-indicated. ACTH, or if this fails, diazepam or nitrazepam, can be used to abolish seizures in infantile spasms. Diazepam is the drug of choice in status epilepticus; given intravenously in status grand mal, or intramuscularly or intravenously in status petit mal and status focal seizures.
Adverse effects of anticonvulsants can be divided into three groups: those which are a result of intoxication and which are related to elevated plasma levels. These include nystagmus, sedation and unsteadiness, and are usually, but not inevitably, a consequence of overdosage. The second category includes the side-effects, which occur as by-products of the pharmacological action of the drugs when used in the usual doses and with plasma levels in the desirable range. They may be more severe with higher doses. Frequent among these are gum hypertrophy with phenytoin, photophobia with trimethadione and depression of folate with hydantoins and barbiturates. Idiosyncratic reactions comprise the third category of unwanted effects; these are unpredictable, are unrelated to dose or plasma level and presumably occur on an allergic basis. Most frequent are skin rashes, and most dangerous are blood dyscrasias. The dysmorphogenic effects, the effects on the pregnant mother and on the newborn are reviewed.
Similar content being viewed by others
References
Booker, H.E.; Hosokowa, K.; Burdette, R.D. and Darcey, B.: A clinical study of serum primidone levels. Epilepsia 11: 395–402 (1970).
Booker, H.E.; Tormay, A. and Toussaint, J.: Concurrent administration of phenobarbital and diphenylhydantoin: Lack of an interference effect. Neurology 21: 383–385 (1971).
Borofsky, L; Louis, S.; Roginsky, M. and Kutt, H: The pharmacology and efficacy of diphenylhydantoin in children. Neurology 22: 421 (1972).
Brennan, R.W.; Dehejia, H; Kutt, H; Verebely, K. and McDowell, F.: Diphenylhydantoin intoxication attendant to slow inactivation of isoniazid. Neurology 20: 687–693 (1970).
Buchanan, R.A.; Heffelfinger, J.C and Weiss, CF.: The effect of phenobarbital on diphenylhydantoin metabolism in children. Pediatrics 43: 114–116 (1969).
Buchthal, F. and Svensmark, O.: Serum concentration of diphenylhydantoin (Phenytoin) and phenobarbital and their relation to therapeutic and toxic effects. Psychiatria Neurologica Neurochirurgia 74: 117–136(1971).
Cantu, R.C. and Schwab, R.S.: Ceruloplasmin rise and PBI fall in serum due to diphenylhydantoin. Archives of Neurology 15: 393–396 (1966).
Chamberlin, H.R.; Waddell, W.J. and Butler, T.C.: A study of the product of demethylation of trimethadione in the control of petit mal epilepsy. Neurology 75: 449–454 (1965).
Christensen, L.K. and Skovsted, L.: Inhibition of drug metabolism by chloramphenicol. Lancet 2: 1397–1399 (1969).
Conney, A.H.: Pharmacological implications of microsomal enzyme induction. Pharmacological Reviews 19: 317–366 (1967).
Cram, R.L.; Juchau, M.R. and Fouts, J.R.: Differences in hepatic drug metabolism in various rabbit strains before and after treatment with phenobarbital. Proceedings of the Society for Experimental Biology andMedicine 118: 872–875 (1965).
Cucinell, S.A.; Conney, A.H.; Sansur, M.S. and Burns, J.J.: Drug interactions in man. I. Lowering effect of phenobarbital on plasma levels of bishydroxy-coumarin (Dicoumarol) and diphenylhydantoin (Dilantin). Clinical Pharmacology and Therapeutics 6: 420–429 (1965).
Dam, M.: Organic changes in phenytoin-intoxicated pigs. Acta Neurologica Scandinavica 42: 491–494 (1966).
Davies, J.E., Edmundson, W.F.: Carter, C.H. and Barquet, A.: Effect of anticonvulsant drugs on dicophane (DDT) residues in man. Lancet 2: 7–9 (1969).
Del Cerro, M.P. and Snider, R.S.: Studies on Dilantin intoxication. Neurology 17: 452–466 (1967).
Diamond, W.D. and Buchanan, R.A.: A clinical study of the effect of phenobarbital on diphenylhydantoin plasma levels. Journal of Clinical Pharmacology 10: 306–311(1970).
Eling, T.E., Harbison, R.D.; Becker, B.B. and Fouts, J.R.: Diphenylhydantoin effect on neonatal and adult rat hepatic drug metabolism. Journal of Pharmacology and Experimental Therapeutics 171: 127–134 (1971).
Frantzen, E.; Hansen, J.M.; Hansen, O.E. and Kristensen, M.: Phenytoin (Dilantin) intoxication. Acta Neurol. Scand. 43: 440–446 (1967).
Frey, H.H.; Kampmann, E. and Nielsen, C.K.: Study on combined treatment with phenobarbital and diphenylhydantoin. Acta Pharmacologica and Toxicologica 26: 284 (1968).
Garrettson, L.K.; Perel, J.M. and Dayton, P.G.: Methylphenidate interaction with both anticonvulsants and ethyl biscoumacetate. Journal of the American Medical Association 207: 2053–2056 (1969).
Garrettson, L.K. and Dayton, P.G.: Disappearance of phenobarbital and diphenylhydantoin from serum of children. Clinical Pharmacology and Therapeutics 11: 674–679 (1970).
Gerber, N. and Arnold, K: The effect of diphenylpiperazine compounds and other agents on diphenylhydantoin, zoxazolamine and hexobarbital metabolism. Journal of Pharmacology and Experimental Therapeutics 164: 232–238 (1968).
Gerber, N. and Arnold, K.: Studies on the metabolism of diphenylhydantoin in mice. Journal of Pharmacology and Experimental Therapeutics 167: 77–90 (1969).
German, J.; Ehlers, K.H.; Kowal, A.; De George, F.V.; Engle, M.A. and Passarge, E.: Possible teratogenicity of trimethadione and paramethadione. Lancet 2: 261–262 (1970).
German, J.; Kowal, A. and Ehlers, K.H.: Trimethadione and human teratogenesis Teratology 3: 349–362 (1970b).
Haerer, A.F. and Grace, J.B.: Studies of anticonvulsant levels in epileptics. Acta Neurologica Scandinavica 45: 18–31 (1969).
Hansen, J.M.; Kristensen, M.; Skovsted, L. and Christensen, L.K.: Dicoumarol-induced diphenylhydantoin intoxication. Lancet 2: 265–266 (1966).
Hansen, J.M.; Kristensen, M. and Skovsted, L: Sulthiame (Ospolot) as inhibitor of diphenylhydantoin metabolism. Epilepsia 9: 17–22 (1968).
Hansen, J.M.; Siersbaek-Nielsen, K; Kristensen, M.; Skovsted, L. and Christensen, L.K.: Effect of diphenylhydantoin on the metabolism of dicoumarol in man. Acta Medica Scandinavica 189: 15–19 (1971a).
Hansen, J.M.; Siersbaek-Nielsen, K. and Skovsted, L.: Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man. Clinical Pharmacology and Therapeutics 12: 539–543 (1971b).
Harbison, R.D. and Becker, B.A.: Relation of dosage and time of administration of diphenylhydantoin to its teratogenic effect in mice. Teratology 2: 305 (1969).
Hirschmann, J.: Die Kontrolle der Diphenylhydantoin-Dosierung bei Anfallsleiden durch Bestimmung der Serumspiegel. Medizinische Welt 5: 705–750 (1969).
Karlin, J.M. and Kutt, H.: Acute diphenylhydantoin intoxication following halothane anesthesia. J. Pediat. 76: 941–944 ( 1970).
Kater, R.M.H.; Roggin, G.; Tobon, F.; Zieve, P. and Iber, F.L.: Increased rate of clearance of drugs from the circulation of alcoholics. American Journal of Medical Sciences 258: 35–39 (1969).
Kiørboe, E.: Phenytoin intoxication during treatment with Antabuse (Disulfiram). Epilepsia 7: 246–249 (1966).
Kokenge, R.; Kutt, H. and McDowell, F.: Neurological sequela following Dilantin (R) overdose in a patient and in experimental animals. Neurology 15: 823–829 (1965).
Kristensen, M.; Hansen, J.M. and Skovsted, L: The influence of phenobarbital on the half-life of diphenylhydantoin in man. Acta Medica Scandinavica 185: 347–350 (1969).
Kupferberg, H.J.; Jeffery, W. and Hunninghake, D.B.: Effect of methylphenidate on plasma anticonvulsant levels. Clinical Pharmacology and Therapeutics 13: 201–204 (1972).
Kutt, H. and McDowell, F.: Management of epilepsy with diphenylhydantoin sodium. Journal of the American Medical Association 203: 969–972 (1968).
Kutt, H.;Haynes, J; Verebely, K. and McDowell, F.: The effect of phenobarbital on plasma diphenylhydantoin level and metabolism in man and in rat liver microsomes. Neurology 19: 611–616 (1969).
Kutt, H. and Verebely, K: Metabolism of diphenylhydantoin by rat liver microsomes. I. Characteristics of the reaction. Biochemical Pharmacology 19: 675–686 (1970).
Kutt, H; Waters, L. and Fouts, J.H.: Diphenylhydantoin-induced difference spectra with rat liver microsomes. Chemical-Biological Interactions 2: 195–202 (1970a).
Kutt, H.; Waters, L. and Fouts, J.R.: The effects of some stimulators (inducers) of hepatic microsomal drug-metabolizing enzyme activity on substrate-induced difference spectra in rat liver microsomes. J. Pharmacol. Exp. Ther. 179: 101–113 (1971).
Kutt, H; Brennan, R.; Dehejia, H. and Verebely, K.: Diphenylhydantoin intoxication. A complication of isoniazid therapy. American Review of Respiratory Disease 101: 377–384 (1970b).
Kutt, H: Biochemical and genetic factors regulating Dilantin metabolism in man. Annals of the New York Academy of Sciences 179: 704–722 (1971).
Kutt, H. and Fouts, J.R.: Diphenylhydantoin metabolism by rat liver microsomes and some of the effects of drug or chemical pretreatment on diphenylhydantoin metabolism by rat liver microsomal preparations. Journal of Pharmacology and Experimental Therapeutics 176: 11–26 (1971).
Kwalick, D.S.: Anticonvulsants and DDT residues. Journal of the American Medical Association 215: 120–121 (1971).
Livingston, S.: Drug therapy for epilepsy. (Illinois 1966).
Louis, S.; Kutt, H. and McDowell, F: The cardiocirculatory changes caused by intravenous Dilantin and its solvents. American Heart Journal 74: 523–529 (1967).
Lovelace, R.E. and Horwitz, S.J.: Peripheral neuropathy in long-term diphenylhydantoin therapy. Archives of Neurology 18: 69–77 (1968).
Meadow, S.R.: Congenital abnormalities and anticonvulsant drugs. Proceedings of the Royal Society of Medicine 63: 48–49 (1970).
Meikle, A.W.; Jubiz, W.; Matsakura, S.; West, CD. and Tyler, F.H: Effect of diphenylhydantoin on the metabolism of metyrapone and release of ACTH in man. Journal of Clinical Endocrinology and Metabolism 29: 1553–1558 (1969).
Millichap, G.: Drug therapy and management of the child with epilepsy. Drug Therapy 1: 15–29 (1971).
Mirkin, B.L.: Diphenylhydantoin: placental transport, fetal localization, neonatal metabolism, and possible teratogenic effects. Journal of Pediatrics 78: 329–337 (1971).
Mirkin, B.L. and Wright, F.: Drug interactions: Effect of methylphenidate on the disposition of diphenylhydantoin in man. Neurology 21: 1123–1128 (1971).
Morselli, P.L.; Rizzo, M. and Garattini, S.: Interaction between phenobarbital and diphenylhydantoin in animals and in epileptic patients. Annals of the New York Academy of Sciences 179: 88–107 (1971).
Mountain, K.R.; Hirsh, J. and Gallus, A.S.: Neonatal coagulation defect due to anticonvulsant drug treatment in pregnancy. Lancet 1: 265 (1970).
Nicol, C.F.; Tutton, J.C. and Smith, B.H.: Parenteral diazepam in status epilepticus. Neurology 19: 332–343 (1969).
Nielsen, M.H.; Dam, M. and Klinken, L.: The ultrastructure of Purkinje cells in diphenylhydantoin intoxicated rats. Experimental Brain Research 12: 447–456 (1971).
Olesen, O.V.: Disulfiramum (Antabuse) as inhibitor of phenytoin metabolism. Acta Pharmacologica et Toxicologjca 24: 317–322 (1966).
Olesen, V. and Jensen, N.: Drug-interaction between sulthiame (Ospolot ®) and phenytoin in the treatment of epilepsy. Danish Medical Bulletin 16: 154–158 (1969).
Putnam, TJ. and Rothenberg, S.F.: Results of intensive (narcosis) and standard medical treatment of epilepsy. Journal of the American Medical Association 152: 1400–1406 (1953).
Reynolds, E.H.: Iatrogenic disorders in epilepsy; in Williams Modern Trends in Neurology 5. pp 271–286 Appleton-Century Crofts, New York (1970).
Richens, A. and Rowe, D.J.F.: Disturbance of calcium metabolism by anticonvulsant drugs. British Medical Journal 4: 73–76 (1970).
Rümke, CL. and Noordhoek, J.: The influence of Lynestrenol on the rate of metabolism of phenobarbital, phenytoin and hexobarbital in mice. European Journal of Pharmacology 6: 163–168 (1969).
Sharer, L. and Kutt, H: Intravenous administration of diazepam. Effects on penicillin-induced focal seizures in the cat. Archives of Neurology 24: 169–175 (1971).
Solomon, G.E.; Hilgartner, M. W. and Kutt, H: Coagulation defects caused by diphenylhydantoin. Neurology (abstract) 21: 394 (1971).
Solomon, H.M. and Schrogie, J.J.: The effect of phenyramidol on the metabolism of diphenylhydantoin. Clinical Pharmacology and Therapeutics 8: 554–556 (1967).
Solomon, H.M.; Reich, S.; Spirt, N. and Abrams, W.B.: Interactions between digitoxin and other drugs in vitro and in vivo. Annals of the New York Academy of Sciences 79: 362–369 (1971).
Unger, AM. and Sklaroff, HJ.: Fatalities following intravenous use of sodium diphenylhydantoin for cardiac arrhythmias. Journal of the American Medical Association 200: 335–336 (1967).
Utterback, R.A.; Ojeman, R. and Malek, J.: Paren-chymatous cerebellar degeneration with Dilantin intoxiciation. Journal of Neuropathology and experimental Neurology 17: 516–519 (1958).
Vajda, FJE.; Prineas, RJ. and Lovell, R.R.H.: Interaction between phenytoin and the benzodiazepines. British Medical Journal 1: 346 (1971).
Vesell, E.S. and Page, J.G.: Genetic control of the pheno-barbital-induced shortening of plasma antipyrine half-life in man. Journal of Clinical Investigation 48: 2202–2209 (1969).
Wallis, W.; Kutt, H. and McDowell, F: Intravenous diphenylhydantoin in treatment of acute repetitive seizures. Neurology 18: 513–525 (1968).
Watson, M.; Gabica, J. and Benson, W.W.: Serum organochlorine pesticides in mentally retarded patients on differing drug regimens. Clinical Pharmacology and Therapeutics 13: 186–192 (1972).
Author information
Authors and Affiliations
Additional information
Second of two parts (Part I: Patho-physiology and pharmacological Aspects)
See subject index in each issue for further indexing terms.
Rights and permissions
About this article
Cite this article
Kutt, H., Louis, S. Anticonvulsant Drugs. Drugs 4, 256–282 (1972). https://doi.org/10.2165/00003495-197204030-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-197204030-00004